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1. Introduction {#efs25886-sec-0002}
===============

1.1. Background and Terms of Reference {#efs25886-sec-0003}
--------------------------------------

Regulation (EC) No 1831/2003[1](#efs25886-note-1007){ref-type="fn"} establishes the rules governing the Community authorisation of additives for use in animal nutrition. In particular, Article 4(1) of that Regulation lays down that any person seeking authorisation for a feed additive or for a new use of a feed additive shall submit an application in accordance with Article 7.

The European Commission received two requests from Archer Daniels Midland Company[2](#efs25886-note-1008){ref-type="fn"} for authorisation of the products [l]{.smallcaps}‐lysine monohydrochloride and concentrated liquid [l]{.smallcaps}‐lysine (base), produced by two different strains of *Corynebacterium glutamicum*, when used as a feed additives for all animal species (category: nutritional additives; functional group: amino acids, their salts and analogues).

According to Article 7(1) of Regulation (EC) No 1831/2003, the Commission forwarded the applications to the European Food Safety Authority (EFSA) as applications under Article 4(1) (authorisation of a feed additive or new use of a feed additive). The particulars and documents in support of the two applications were considered valid by EFSA as of 8 of May 2018 and as of 1 October 2018, respectively.

According to Article 8 of Regulation (EC) No 1831/2003, EFSA, after verifying the particulars and documents submitted by the applicant, shall undertake an assessment in order to determine whether the feed additive complies with the conditions laid down in Article 5. EFSA shall deliver an opinion on the safety for the target animals, consumer, user and the environment and on the efficacy of the products [l]{.smallcaps}‐lysine monohydrochloride and concentrated liquid [l]{.smallcaps}‐lysine (base) produced by fermentation using genetically modified strains of *Corynebacterium glutamicum* (NRRL B‐67439 or NRRL B‐67535), when used under the proposed conditions of use (see Section [3.2.5](#efs25886-sec-0022){ref-type="sec"}).

1.2. Additional information {#efs25886-sec-0004}
---------------------------

The active substance of the two products under application, [l]{.smallcaps}‐lysine, is produced by genetically modified strains of *C. glutamicum* (NRRL B‐67439 or NRRL B‐67535).

[l]{.smallcaps}‐Lysine produced using different microbial strains is currently authorised for its use in all animal species as a nutritional additive.[3](#efs25886-note-1009){ref-type="fn"}

[l]{.smallcaps}‐Lysine is authorised for use in food,[4](#efs25886-note-1010){ref-type="fn"} cosmetics[5](#efs25886-note-1011){ref-type="fn"} and as a veterinary medicinal product.[6](#efs25886-note-1012){ref-type="fn"} ^,^ [7](#efs25886-note-1013){ref-type="fn"}

[l]{.smallcaps}‐Lysine hydrochloride is described in a monograph of the European Pharmacopoeia (PhEur 9th edition, [2017](#efs25886-bib-0031){ref-type="ref"}) monograph 01/2008:0930.

The Scientific Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) has published several opinions on the safety and efficacy of [l]{.smallcaps}‐lysine: some of them on [l]{.smallcaps}‐lysine sulphate produced by fermentation using different strains of *C. glutamicum* for all animal species (EFSA FEEDAP Panel, [2007](#efs25886-bib-0032){ref-type="ref"}, [2015a](#efs25886-bib-0007){ref-type="ref"},[b](#efs25886-bib-0008){ref-type="ref"}, [2016b](#efs25886-bib-0011){ref-type="ref"}) or using a strain of *Escherichia coli* (EFSA FEEDAP Panel, [2017a](#efs25886-bib-0012){ref-type="ref"}, [2017b](#efs25886-bib-0013){ref-type="ref"}, [2017c](#efs25886-bib-0014){ref-type="ref"}, [2017d](#efs25886-bib-0015){ref-type="ref"}a); and others on the safety and efficacy of concentrated liquid [l]{.smallcaps}‐lysine (base), concentrated liquid [l]{.smallcaps}‐lysine monohydrochloride and/or [l]{.smallcaps}‐lysine monohydrochloride for all animal species (EFSA FEEDAP Panel, [2013](#efs25886-bib-0005){ref-type="ref"}, [2014](#efs25886-bib-0006){ref-type="ref"}, [2015c](#efs25886-bib-0008){ref-type="ref"}, [2016a](#efs25886-bib-0010){ref-type="ref"}), produced by fermentation using different strains of *E. coli* or *C. glutamicum* (EFSA FEEDAP Panel, [2016b](#efs25886-bib-0011){ref-type="ref"}, [2019a](#efs25886-bib-0017){ref-type="ref"}, [b](#efs25886-bib-0018){ref-type="ref"},[c](#efs25886-bib-0019){ref-type="ref"},d).

The Scientific Panel on Food Additives, Flavourings, Processing Aids and Materials in contact with Food (AFC) issued an opinion on [l]{.smallcaps}‐lysine and its monohydrochloride salt when used as a flavouring compound (EFSA, [2008](#efs25886-bib-0033){ref-type="ref"}; EFSA AFC Panel, [2010](#efs25886-bib-0034){ref-type="ref"}). The Scientific Panel on Dietetic Products, Nutrition and Allergies (NDA) issued three opinions on the substantiation of health claims related to [l]{.smallcaps}‐lysine (EFSA NDA Panel, [2011a](#efs25886-bib-0035){ref-type="ref"},[b](#efs25886-bib-0036){ref-type="ref"}, [2014](#efs25886-bib-0037){ref-type="ref"}). The Scientific Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF) issued an opinion on consideration of 88 flavouring substances considered by EFSA for which EU production volumes/anticipated production volumes have been submitted on request by DG SANCO, including [l]{.smallcaps}‐lysine (FLAVIS No 17.026) as a flavouring compound (EFSA CEF Panel, [2011](#efs25886-bib-0038){ref-type="ref"}).

Bacterial protein from *C. glutamicum* as well as by‐products from the production of amino acids with *C. glutamicum* (the cells of the micro‐organisms have to be inactivated or killed) are listed in the Catalogue of feed materials (Commission Regulation (EU) 2017/2017).[8](#efs25886-note-1014){ref-type="fn"}

2. Data and methodologies {#efs25886-sec-0005}
=========================

2.1. Data {#efs25886-sec-0006}
---------

The present assessment is based on data submitted by the applicant in the form of two different technical dossiers[9](#efs25886-note-1015){ref-type="fn"} in support of the authorisation request for the use of [l]{.smallcaps}‐lysine monohydrochloride and concentrated liquid [l]{.smallcaps}‐lysine (base) produced by fermentation using genetically modified strains of *C. glutamicum* (NRRL B‐67439 or NRRL B‐67535) as feed additives.

The FEEDAP Panel used the data provided by the applicant together with data from other sources, such as previous risk assessments by EFSA or other expert bodies, other scientific reports to deliver the present output.

EFSA has verified the European Union Reference Laboratory (EURL) report as it relates to the methods used for the control of the [l]{.smallcaps}‐lysine monohydrochloride and concentrated liquid [l]{.smallcaps}‐lysine (base) produced by fermentation using *C. glutamicum* NRRL B‐67439 or NRRL B‐67535 in animal feed. The Executive Summaries of the EURL reports can be found in Annexes [A](#efs25886-sec-1002){ref-type="sec"} and [B](#efs25886-sec-1002){ref-type="sec"}.[10](#efs25886-note-1016){ref-type="fn"}

2.2. Methodologies {#efs25886-sec-0007}
------------------

The approach followed by the FEEDAP Panel to assess the safety and the efficacy of [l]{.smallcaps}‐lysine monohydrochloride and concentrated liquid [l]{.smallcaps}‐lysine (base) produced by fermentation using *C. glutamicum* NRRL B‐67439 or NRRL B‐67535 is in line with the principles laid down in Regulation (EC) No 429/2008[11](#efs25886-note-1017){ref-type="fn"} and the relevant guidance documents: Guidance on studies concerning the safety of use of the additive for users/workers (EFSA FEEDAP Panel, [2012](#efs25886-bib-0004){ref-type="ref"}), Guidance on the identity, characterisation and conditions of use of feed additives (EFSA FEEDAP Panel, [2017a](#efs25886-bib-0012){ref-type="ref"}, [2017b](#efs25886-bib-0013){ref-type="ref"}, [2017c](#efs25886-bib-0014){ref-type="ref"}, [2017d](#efs25886-bib-0015){ref-type="ref"}), Guidance on the characterisation of microorganisms used as feed additives or as production organisms (EFSA FEEDAP Panel, [2018](#efs25886-bib-0016){ref-type="ref"}), Guidance on the assessment of the safety of feed additives for the target species (EFSA FEEDAP Panel, [2017a](#efs25886-bib-0012){ref-type="ref"}, [2017b](#efs25886-bib-0013){ref-type="ref"}, [2017c](#efs25886-bib-0014){ref-type="ref"}, [2017d](#efs25886-bib-0015){ref-type="ref"}c), Guidance on the assessment of the safety of feed additives for the consumer (EFSA FEEDAP Panel, [2017a](#efs25886-bib-0012){ref-type="ref"}, [2017b](#efs25886-bib-0013){ref-type="ref"}, [2017c](#efs25886-bib-0014){ref-type="ref"}, [2017d](#efs25886-bib-0015){ref-type="ref"}d), Guidance for assessing the safety of feed additives for the environment (EFSA FEEDAP Panel, [2017a](#efs25886-bib-0012){ref-type="ref"}, [2017b](#efs25886-bib-0013){ref-type="ref"}, [2017c](#efs25886-bib-0014){ref-type="ref"}, [2017d](#efs25886-bib-0015){ref-type="ref"}a) and Guidance on the assessment of the efficacy of feed additives (EFSA FEEDAP Panel, [2018](#efs25886-bib-0016){ref-type="ref"}).

3. Assessment {#efs25886-sec-0008}
=============

The product subject of this application is [l]{.smallcaps}‐lysine in the forms of monohydrochloride (HCl) or concentrated liquid [l]{.smallcaps}‐lysine (base) produced by fermentation with genetically modified strains of *C. glutamicum*. The product under application is intended to be used in feed and water for drinking for all animal species and categories as a nutritional additive, under the functional group 'amino acids, their salts and analogues'.

3.1. Manufacturing process {#efs25886-sec-0009}
--------------------------

■■■■■[■■■■■](#efs25886-note-1018){ref-type="fn"}■■■■■[■■■■■](#efs25886-note-1019){ref-type="fn"}

3.2. Characterisation of [l]{.smallcaps}‐lysine HCl and concentrated liquid [l]{.smallcaps}‐lysine (base) produced using *C. glutamicum* NRRL B‐67439 {#efs25886-sec-0010}
-----------------------------------------------------------------------------------------------------------------------------------------------------

### 3.2.1. Characterisation of the production microorganism {#efs25886-sec-0011}

The additive is produced by a genetically modified strain of *C. glutamicum,* which is deposited ■■■■■ as *C. glutamicum* NRRL B‐67439.[■■■■■](#efs25886-note-1020){ref-type="fn"}

The susceptibility of the production strain to the antibiotics listed in the Guidance on the characterisation of microorganisms used as feed additives or as production organisms (EFSA FEEDAP Panel, [2018](#efs25886-bib-0016){ref-type="ref"}) for '*Corynebacterium* and other Gram +' was tested ■■■■■[■■■■■](#efs25886-note-1021){ref-type="fn"} All of the minimum inhibitory concentration (MIC) values found well below the cut‐off values of the above mentioned guidance. According to the guidance, the whole genome sequence (WGS) of the production strain was interrogated for the presence of antimicrobial resistance (AMR) genes ■■■■■[■■■■■](#efs25886-note-1022){ref-type="fn"} No AMR genes were found.

#### 3.2.1.1. Information related to the genetically modified microorganism {#efs25886-sec-0012}

*a*)*Characteristics of the recipient or parental microorganism* [17](#efs25886-note-1023){ref-type="fn"}

■■■■■[■■■■■](#efs25886-note-1024){ref-type="fn"}■■■■■[■■■■■](#efs25886-note-1025){ref-type="fn"}

*b*)*Characterisation of the donor organism*

■■■■■

■■■■■

■■■■■

c)*Description of the genetic modification process*

■■■■■ ■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■

■■■■■[■■■■■](#efs25886-note-1026){ref-type="fn"}

■■■■■[■■■■■](#efs25886-note-1027){ref-type="fn"}

### 3.2.2. Characterisation of [l]{.smallcaps}‐lysine HCl {#efs25886-sec-0013}

[l]{.smallcaps}‐Lysine HCl (International Union of Pure and Applied Chemistry (IUPAC) name: (2*S*)‐2,6‐diaminohexanoic acid monohydrochloride, synonym [l]{.smallcaps}‐lysine hydrochloride, a compound identified with the Chemical Abstracts Service (CAS) No 657‐27‐2 and the European Inventory of Existing Commercial Chemical Substances (EINECS) No 211‐519‐9), has a molecular weight of 182.65 g/mol. The theoretical content of lysine in lysine monohydrochloride is 80%. The molecular formula is NH~2~--(CH~2~)~4~--CH(NH~2~)--COOH--HCl and the molecular structure is given in Figure [1](#efs25886-fig-0001){ref-type="fig"}.

![Molecular structure of [l]{.smallcaps}‐lysine HCl](EFS2-17-e05886-g001){#efs25886-fig-0001}

The specification is for an additive containing ≥ 98.5% [l]{.smallcaps}‐lysine HCl, ≤ 1.5% water and \< 1% unidentified material.[22](#efs25886-note-1028){ref-type="fn"}

The average lysine content analysed in five batches was 79.3% (range 79.2--79.5%) on an 'as is' basis.[23](#efs25886-note-1029){ref-type="fn"} The content of chloride was on average 18.6% (range 18.5--18.7%). The water content was in the range 0.15--0.24%. Other analysed components were (average values of five batches) 0.02% cadaverine, 0.09% crude fat, 0.01% sulfate, 0.06% other free amino acids, 0.07% protein (hydrolysed amino acids minus free amino acids other than lysine) and 0.29% of other components identified by liquid chromatography/mass spectrometry (LC/MS).[24](#efs25886-note-1030){ref-type="fn"} The concentration of lysine HCl in the additive was on average 98.1% on a dry matter basis.[25](#efs25886-note-1031){ref-type="fn"} The amount of identified material was 98.9% on a dry matter basis.

The applicant submitted analytical data on specific optical rotation of five batches of the additive and the values was on average 19.4 (range +17.5 to +20.7).[26](#efs25886-note-1032){ref-type="fn"} Three of the five batches tested were outside of the reference range specified in the food chemicals code of the United States Pharmacopoeia ([2010](#efs25886-bib-0039){ref-type="ref"}) (+20.3 to +21.5°).

#### 3.2.2.1. Impurities of [l]{.smallcaps}‐lysine HCl {#efs25886-sec-0014}

Heavy metals (cadmium, lead and mercury) and arsenic were analysed in five batches of the final product and all values were below the limit of detection (LOD) except one batch that contained 19 μg lead/kg.[27](#efs25886-note-1033){ref-type="fn"} Dioxins (polychlorinated dibenzodioxins (PCDDs), and polychlorinated dibenzofurans (PCDFs) and dioxin‐like polychlorinated biphenyls (co‐planar PCBs) were analysed in five batches of the final product. PCDD/F concentrations were on average 0.0884 TEQ‐WHO ng/kg, PCBs were on average 0.0032 TEQ‐WHO ng/kg and the sum of PCDD/F and PCBs were on average 0.0915 TEQ‐WHO ng/kg.[26](#efs25886-note-1032){ref-type="fn"} The amount of the above‐mentioned impurities does not raise safety concerns.

As regards the microbial contamination, five batches were analysed and in all batches *Salmonella* spp. was absent (100‐g samples); aerobic plate counts were \< 100 colony forming units (CFU)/g; coliforms and *E. coli* were \< 3 CFU/g; yeasts, moulds and *Staphylococcus* coagulase positive were \< 100 CFU/g; and *Pseudomonas aeruginosa* was absent (25‐g samples). Mycotoxin concentrations were measured in three batches of the additive and all batches yielded the same result: aflatoxin B1 was \< 0.5 μg/kg, aflatoxin B2 was \< 0.3 μg/kg, aflatoxin G1 was \<0.7 μg/kg, aflatoxin G2 was \<0.2 μg/kg, Deoxynivalenol (DON) and fumonisin B2 were \< 10 μg/kg, fumonisin B1 was \< 4 μg/kg, fumonisin B3 was \< 8 μg/kg, ochratoxin was \< 0.8 μg/kg, T‐2 toxin was \< 9 μg/kg and zearalenone was \< 7 μg/kg.[28](#efs25886-note-1034){ref-type="fn"}

The presence of viable cells of the production strain was investigated ■■■■■[■■■■■](#efs25886-note-1035){ref-type="fn"}■■■■■ and no colonies were detected. ■■■■■

The absence of DNA was confirmed ■■■■■

#### 3.2.2.2. Physical characteristics of [l]{.smallcaps}‐lysine HCl {#efs25886-sec-0015}

The additive is a tan coloured granulate with a slight fermentation odour. Its water solubility is 500--600 g/L at 25°C.[30](#efs25886-note-1036){ref-type="fn"} The density (three batches analysed) ranged from 562.5 to 607.3 g/L.[31](#efs25886-note-1037){ref-type="fn"}

The dusting potential was measured in three batches of the final product (Stauber--Heubach method) and the values ranged from 0.1 to 0.6 g/m^3^.[32](#efs25886-note-1038){ref-type="fn"} The particle size distribution (three batches analysed by laser diffraction) showed that the fractions \< 100, \< 52 and \< 18 μm diameter ranged 1.1--3.7, 0.6--2.8 and 0--1.4%, respectively.[33](#efs25886-note-1039){ref-type="fn"}

#### 3.2.2.3. Stability and homogeneity of [l]{.smallcaps}‐lysine HCl {#efs25886-sec-0016}

The applicant did not provide data on the shelf life, stability in premixtures and in feedingstuffs and on the capacity of the [l]{.smallcaps}‐lysine HCl under assessment to distribute homogeneously in feed. The data provided corresponded to a [l]{.smallcaps}‐lysine HCl produced with different strains of *C. glutamicum* (i.e. strain NRRL B‐50775 for the stability (EFSA FEEDAP Panel, [2019b](#efs25886-bib-0018){ref-type="ref"}); and strain NRRL B‐50547 for the homogeneity (EFSA FEEDAP Panel, [2016b](#efs25886-bib-0011){ref-type="ref"})).

Since the physical characteristics, the purity and the production process are similar, the FEEDAP Panel considers the previous data as representative for the product under assessment.

### 3.2.3. Characterisation of concentrated liquid [l]{.smallcaps}‐lysine (base) {#efs25886-sec-0017}

[l]{.smallcaps}‐Lysine (IUPAC name (2*S*)‐2,6 diaminohexanoic acid; synonym α,ε diaminocaproic acid), a compound identified with the CAS No 56‐87‐1 and the EINECS No 200‐294‐2, has a molecular weight of 146.2 g/mol. The molecular formula is NH~2~--(CH~2~)~4~--CH(NH~2~)--COOH. The molecular structure is given in Figure [2](#efs25886-fig-0002){ref-type="fig"}.

![Molecular structure of [l]{.smallcaps}‐lysine](EFS2-17-e05886-g002){#efs25886-fig-0002}

The product is specified to contain ≥ 50 % lysine, ≤ 50 % water, and about 1% of unidentified material.

The specification was confirmed by analytical data from five batches which contained on average 50.8 % lysine 'as is' (range 50.3--51.3 %).[34](#efs25886-note-1040){ref-type="fn"} The water content was 46.6 % (range 45.5--47.7 %). Other analysed constituents were (average values) 0.7% protein (hydrolysed amino acids minus free amino acids other than lysine), 0.3% organic acids, 0.3% ash, 0.3% other amino acids, 0.2% crude fat, 0.05% sugars, 0.03% sulfate, 0.02% chlorine, 0.02% cadaverine, 0.01% ammonia and 1.2% of substances identified by LC/MS.[35](#efs25886-note-1041){ref-type="fn"}

On a dry matter basis, the sum of quantified components was on average 100.5 % (range 98.8--102.7%). [l]{.smallcaps}‐Lysine represented on average 95.2% (range 94.0--96.6%) of the total dry matter content.

#### 3.2.3.1. Impurities {#efs25886-sec-0018}

Heavy metals (cadmium, lead and mercury) and arsenic were analysed in five batches of the final product and all values were below the LOD.[36](#efs25886-note-1042){ref-type="fn"} PCDDs, PCDFs and co‐planar PCBs were analysed in five batches of the final product. PCDD/F concentrations were on average 0.1200 TEQ‐WHO ng/kg, PCBs were on average 0.0068 TEQ‐WHO ng/kg and the sum of PCDD/F and PCBs were on average 0.1266 TEQ‐WHO ng/kg.[37](#efs25886-note-1043){ref-type="fn"} The amount of the abovementioned impurities does not raise safety concerns.

As regards the microbial contamination, five batches were analysed and in all batches *Salmonella* spp. was absent (100‐g samples); aerobic plate counts were \< 100 CFU/g; coliforms and *E. coli* were \< 3 CFU/g; yeasts, moulds and *Staphylococcus* coagulase positive were \< 100 CFU/g; and *Pseudomonas aeruginosa* was absent (25‐g samples). Mycotoxin concentrations were measured in three batches of the additive and all batches yielded the same result: aflatoxin B1 was \< 0.5 μg/kg, aflatoxin B2 was \< 0.3 μg/kg, aflatoxin G1 was \< 0.7 μg/kg, aflatoxin G2 was \< 0.2 μg/kg, DON and fumonisin B2 were \< 10 μg/kg, fumonisin B1 was \< 4 μg/kg, fumonisin B3 was \< 8 μg/kg, ochratoxin was \< 0.8 μg/kg, T‐2 toxin was \< 9 μg/kg and zearalenone was \< 7 μg/kg.[28](#efs25886-note-1034){ref-type="fn"}

The presence of viable cells of the production strain was investigated ■■■■■ and no colonies of the production strain were detected. ■■■■■

The absence of DNA was confirmed ■■■■■

#### 3.2.3.2. Physical characteristics {#efs25886-sec-0019}

The additive is a dark brown liquid with fermentation odour.[38](#efs25886-note-1044){ref-type="fn"} The pH (measured in three batches) was 10.7 in all them.[39](#efs25886-note-1045){ref-type="fn"}

Analytical data of three batches was provided on viscosity and density at 20°C. The viscosity ranged from 55 to 71 mm^2^/s and the density from 1.137 to 1.143 g/cm^3^.[40](#efs25886-note-1046){ref-type="fn"} Vapour pressure analysed in three batches ranged from 16 to 66 kPa.[41](#efs25886-note-1047){ref-type="fn"}

#### 3.2.3.3. Stability and homogeneity {#efs25886-sec-0020}

The applicant did not provide data on the shelf life, stability in premixtures and in feedingstuffs and on the capacity of the product under assessment to distribute homogeneously in feed. The data provided corresponded to a concentrated liquid [l]{.smallcaps}‐lysine base produced with different strains of *C. glutamicum*, i.e. NRRL B‐50775 for the stability (EFSA FEEDAP Panel, [2019b](#efs25886-bib-0018){ref-type="ref"}), and NRRL B‐50547 for the homogeneity in pelleted feed for chickens for fattening (EFSA FEEDAP Panel, [2016b](#efs25886-bib-0011){ref-type="ref"}).

Since the physical characteristics, the purity and the production process are similar, the FEEDAP Panel considers the previous data as representative for the product under assessment.

### 3.2.4. Physico‐chemical incompatibilities in feed {#efs25886-sec-0021}

No physicochemical incompatibilities in feed are expected with other additives, medicinal products or other feed materials.

### 3.2.5. Conditions of use {#efs25886-sec-0022}

According to the applicant, both forms of the additive can be added directly to complete feed, or complementary feedingstuffs. Only [l]{.smallcaps}‐lysine HCl can be used via premixtures. Both forms of the additive are aimed for all animal species. No proposed inclusion levels are provided as the optimal daily allowance in quantitative terms depends on the species, the physiological state of the animal, the performance level and the environmental conditions, as well as the amino acid composition of the unsupplemented diet.

The applicant states that the additive (both forms) can be used in water for drinking but should not be simultaneously administered via water for drinking and feed.[42](#efs25886-note-1048){ref-type="fn"}

3.3. Characterisation of [l]{.smallcaps}‐lysine HCl and concentrated liquid [l]{.smallcaps}‐lysine (base) produced using *C. glutamicum* NRRL B‐67535 {#efs25886-sec-0023}
-----------------------------------------------------------------------------------------------------------------------------------------------------

### 3.3.1. Characterisation of the production microorganism {#efs25886-sec-0024}

The additive is produced by a genetically modified strain of *C. glutamicum,* which is deposited ■■■■■ as *C. glutamicum* NRRL B‐67535.[■■■■■](#efs25886-note-1049){ref-type="fn"} The production strain was confirmed as *C. glutamicum* ■■■■■

The susceptibility of the production strain to the antibiotics listed in the Guidance on the characterisation of microorganisms used as feed additives or as production organisms (EFSA FEEDAP Panel, [2018](#efs25886-bib-0016){ref-type="ref"}) for '*Corynebacterium* and other Gram +' was tested ■■■■■[■■■■■](#efs25886-note-1050){ref-type="fn"} All of the MIC values found fell below the FEEDAP cut‐off values of the above mentioned guidance. The WGS of the production strain was interrogated for the presence of AMR genes ■■■■■[■■■■■](#efs25886-note-1051){ref-type="fn"} No AMR genes were found.

#### 3.3.1.1. Information relating to the genetically modified microorganism {#efs25886-sec-0025}

##### *Characteristics of the recipient or parental microorganism* [46](#efs25886-note-1052){ref-type="fn"} {#efs25886-sec-0026}

■■■■■[■■■■■](#efs25886-note-1053){ref-type="fn"}

##### Characterisation of the donor organism {#efs25886-sec-0027}

■■■■■

■■■■■

■■■■■

##### ■■■■■ {#efs25886-sec-0028}

■■■■■ ■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■

■■■■■

■■■■■[■■■■■](#efs25886-note-1054){ref-type="fn"}

### 3.3.2. Characterisation of the [l]{.smallcaps}‐lysine monohydrochloride {#efs25886-sec-0029}

The specification is for an additive containing ≥ 98.5% [l]{.smallcaps}‐lysine HCl, ≤ 1.5% water, and \< 1% unidentified material.[49](#efs25886-note-1055){ref-type="fn"} The minimum lysine content is 78%.[50](#efs25886-note-1056){ref-type="fn"}

The average lysine content analysed in five batches was 79.8% (range 79.5--80.1%) on an 'as is' basis.[51](#efs25886-note-1057){ref-type="fn"} The content of chloride was on average 18.9% (range 18.8--19.0%). The water content was in the range 0.12--0.17%. Other analysed components were (average values of five batches) 0.003% cadaverine, 0.05% crude fat, 0.02% sulfate, 0.09% other free amino acids, 0.05% protein (hydrolysed amino acids minus free amino acids other than lysine) and 0.25% of other substances identified by LC/MS.[52](#efs25886-note-1058){ref-type="fn"} The concentration of lysine HCl in the additive was on average 98.9% on a dry matter basis (range 98.6--99.3%).[53](#efs25886-note-1059){ref-type="fn"} The amount of identified material was 100.4% on a dry matter basis.

The applicant submitted analytical data on specific optical rotation of five batches and the values ranged from +20.4 to +20.7°, confirming the presence of the [l]{.smallcaps}‐isomer.[54](#efs25886-note-1060){ref-type="fn"}

#### 3.3.2.1. Impurities of [l]{.smallcaps}‐lysine HCl {#efs25886-sec-0030}

Heavy metals (cadmium, lead and mercury), arsenic and antimony were analysed in five batches of the final product and all values were below the LOD.[55](#efs25886-note-1061){ref-type="fn"} PCDDs, PCDFs and co‐planar PCBs were analysed in five batches of the final product. PCDD/F concentrations were on average 0.0860 TEQ‐WHO ng/kg, PCBs were on average 0.0026 TEQ‐WHO ng/kg and the sum of PCDD/F and PCBs were on average 0.0885 TEQ‐WHO ng/kg.[56](#efs25886-note-1062){ref-type="fn"}

Aflatoxins (B1, B2, G1, G2), ochratoxin A, zearalenone, DON, fumonisins B1, B2 and B3 and T‐2 toxin were below the corresponding LOD.[57](#efs25886-note-1063){ref-type="fn"}

Microbiological contamination was analysed in five batches and showed that *Salmonella* spp. was absent in 100 g, *E. coli* and coliforms were \< 3 CFU/g and aerobic plate count, *Pseudomonas*, staphylococci coagulase positive, yeasts and filamentous fungi were \< 10 CFU/g.[58](#efs25886-note-1064){ref-type="fn"}

The concentrations of the aforementioned contaminants/impurities do not raise safety concerns.

The presence of viable cells of the production strain was investigated ■■■■■[■■■■■](#efs25886-note-1065){ref-type="fn"}■■■■■ and no growth was found.

The absence of DNA of the production strain was confirmed ■■■■■

#### 3.3.2.2. Physical characteristics of [l]{.smallcaps}‐lysine HCl {#efs25886-sec-0031}

The additive is a tan coloured granulate with slight fermentation odour, with a water solubility of 500--600 g/L at 25°C.[60](#efs25886-note-1066){ref-type="fn"} Its bulk density (three batches) ranged from 595 to 635 kg/m^3^.[61](#efs25886-note-1067){ref-type="fn"}

Analytical data on dusting potential of three batches of the final product showed values ranging from 0.6 to 4.6 g/m^3^.[62](#efs25886-note-1068){ref-type="fn"} Particle size distribution was measured by laser diffraction in three batches and the fractions of particles with a size \< 100, \< 50 and \< 10 μm (w/v) of diameter ranged 0.6--2.8, 0.6--1.8 and 0.5--0.9%, respectively.[63](#efs25886-note-1069){ref-type="fn"}

#### 3.3.2.3. Stability and homogeneity of [l]{.smallcaps}‐lysine HCl {#efs25886-sec-0032}

The applicant did not provide data on the shelf‐life, stability in premixtures and in feedingstuffs and on the capacity of the [l]{.smallcaps}‐lysine HCl under assessment to distribute homogeneously in feed testing the additive under assessment. The data provided were the same as mentioned above for [l]{.smallcaps}‐lysine HCl produced using *C. glutamicum* NRRL B‐67439 (Section [3.2.2.3](#efs25886-sec-0016){ref-type="sec"}). Since the physical characteristics, the purity and the production process are similar, the FEEDAP Panel considers the previous data as representative for the product under assessment.

The applicant provided information on the stability of the additive under assessment in water for drinking. Three batches were tested at 0.1, 0.5, 1, 5 and 10 g/kg when stored at 16--23 °C for 3 days.[64](#efs25886-note-1070){ref-type="fn"} No losses were detected.

### 3.3.3. Characterisation of concentrated liquid [l]{.smallcaps}‐lysine (base) {#efs25886-sec-0033}

The product is specified to contain ≥ 50 % lysine, ≤ 50 % water and 1% unidentified material.[65](#efs25886-note-1071){ref-type="fn"}

The specification was confirmed by analytical data from 5 batches which contained on average 50.5 % lysine 'as is' (range 50.1--51.7 %).[66](#efs25886-note-1072){ref-type="fn"} The average water content was 44.9% (range 44.5--45.2%). Other analysed constituents (average values) were 0.4% protein (hydrolysed amino acids minus free amino acids other than lysine), 0.3% organic acids, 0.3% ash, 0.6% other amino acids, 0.2% crude fat, 0.04% sugars, 0.09% sulfate, 0.09% chloride, 0.02% cadaverine, 0.01% ammonia, 0.01% phosphate and 1.7% of other identified material.[67](#efs25886-note-1073){ref-type="fn"}

On a dry matter basis, the sum of quantified components was on average 98.3 % (range 97.7--98.8%). [l]{.smallcaps}‐Lysine represented on average 91.6% (range 90.2--92.4%) of the total dry matter.

#### 3.3.3.1. Impurities {#efs25886-sec-0034}

Heavy mtals (cadmium, lead and mercury), arsenic and antimony were analysed in five batches of the final product and all values were below the LOD.[68](#efs25886-note-1074){ref-type="fn"} PCDDs, PCDFs and co‐planar PCBs were analysed in five batches of the final product. PCDD/F concentrations were on average 0.1694 TEQ‐WHO ng/kg, PCBs were on average 0.0056 TEQ‐WHO ng/kg and the sum of PCDD/F and PCBs were on average 0.175 TEQ‐WHO ng/kg.[69](#efs25886-note-1075){ref-type="fn"} Mycotoxins (Aflatoxins B1, B2, G1, G2, ochratoxin A, zearalenone, fumonisins B1, B2 and B3, DON and T‐2 toxin) were found below the LOD.[70](#efs25886-note-1076){ref-type="fn"}

As regards the microbial contamination, *Salmonella* spp. was negative in 100 g samples, coliforms and *E. coli* were \< 3 CFU/g, and aerobic plate count*, Pseudomonas*,*Staphylococcus* coagulase positive, yeasts and moulds were \< 10 CFU/g.[58](#efs25886-note-1064){ref-type="fn"}

The amount of the aforementioned contaminants/impurities does not raise safety concerns.

The presence of viable cells of the production strain was investigated ■■■■■ and no growth was found.

The absence of DNA of the production strain was confirmed ■■■■■

#### 3.3.3.2. Physical characteristics {#efs25886-sec-0035}

The additive is a dark brown liquid with fermentation odour.[71](#efs25886-note-1077){ref-type="fn"} The pH measured in three batches ranged from 10.91 to 10.92.[72](#efs25886-note-1078){ref-type="fn"} Analytical data of three batches was provided on viscosity and specific weight at 20°C. Viscosity ranged from 58 to 72 mm^2^/s, specific weight ranged 1.14--1.15 g/cm^3^. Vapour pressure (three batches analysed) ranged from 13 to 67 kPa.[73](#efs25886-note-1079){ref-type="fn"}

#### 3.3.3.3. Stability and homogeneity {#efs25886-sec-0036}

The applicant did not provide data on the shelf life, stability in premixtures and in feedingstuffs and on the capacity of the product under assessment to distribute homogeneously in feed testing the product under assessment. The data provided were the same as mentioned above for concentrated liquid [l]{.smallcaps}‐lysine (base) produced using *C. glutamicum* NRRL B‐67439 (Section [3.2.3.3](#efs25886-sec-0020){ref-type="sec"}). Since the physical characteristics, the purity and the production process are similar, the FEEDAP Panel considers the previous data as representative for the product under assessment.

The applicant provided information on the stability of the additive under assessment in water for drinking. Three batches were tested at 0.1, 0.5, 1, 5 and 10 g/kg when stored at 16--23°C for 3 days.[64](#efs25886-note-1070){ref-type="fn"} No losses were detected.

### 3.3.4. Physico‐chemical incompatibilities in feed {#efs25886-sec-0037}

No physicochemical incompatibilities in feed are expected with other additives, medicinal products or other feed materials.

### 3.3.5. Conditions of use {#efs25886-sec-0038}

The conditions of use are the same as described above for [l]{.smallcaps}‐lysine HCl and concentrated liquid [l]{.smallcaps}‐lysine (base) produced using *C. glutamicum* NRRL B‐67439 (Section [3.2.5](#efs25886-sec-0022){ref-type="sec"}).

3.4. Safety of [l]{.smallcaps}‐lysine HCl and concentrated liquid [l]{.smallcaps}‐lysine (base) produced by *C. glutamicum* strains NRRL B‐67439 or NRRL B‐67535 {#efs25886-sec-0039}
----------------------------------------------------------------------------------------------------------------------------------------------------------------

### 3.4.1. Safety of the production strains {#efs25886-sec-0040}

For both strains, the recipient organism belongs to a species, *C. glutamicum*, that is considered by EFSA to be suitable for the Qualified Presumption of Safety (QPS) approach to safety assessment when used for production purposes (EFSA, [2007](#efs25886-bib-0001){ref-type="ref"}; EFSA BIOHAZ Panel, [2019](#efs25886-bib-0002){ref-type="ref"}).

The genetic modifications introduced in those strains are ■■■■■ considered to be safe. No AMR ■■■■■ genes■■■■■ are present in the final production strains.

The identity of the strains has been established, the strains are susceptible to the relevant antimicrobials, and the genetic modifications do not raise safety concerns. Therefore, the production strains can be presumed safe when used for production purposes. No viable cells and DNA of the production strain were detected in the additive.

### 3.4.2. Safety for the target species, consumer and environment {#efs25886-sec-0041}

[l]{.smallcaps}‐Lysine requirements of different species (non‐ruminant and ruminant) and animal categories, absorption and metabolic fate of [l]{.smallcaps}‐lysine, and tolerance to [l]{.smallcaps}‐lysine excess in the diet were described in previous opinions (EFSA FEEDAP Panel, [2013](#efs25886-bib-0005){ref-type="ref"}, [2014](#efs25886-bib-0006){ref-type="ref"}).

Both forms of the additive are highly purified. Safety concerns from the additive may derive either from the amino acid or from the residues of the fermentation process/production strain remaining in the final product. The production strains NRRL B‐67439 or NRRL B‐67535 are presumed safe for production purposes and no viable cells or DNA of the production strains were found in the final products; consequently, no safety concerns for target animal, consumers and the environment would rise from the fermentation residues that may be present in the final additives.

The amino acid [l]{.smallcaps}‐lysine, supplemented to feed, will be incorporated into proteins of tissues and/or products of animal origin and any of their potential excess will be metabolised and excreted as urea/uric acid and carbon dioxide. Therefore, the composition of tissues and products of animal origin will not be affected by the use of [l]{.smallcaps}‐lysine in animal nutrition.

The products do not pose any environmental safety concern associated with the production strains. The amino acid [l]{.smallcaps}‐lysine is a physiological and natural component of the proteins of living organisms. When consumed, it will be absorbed, and the non‐absorbed fraction will be incorporated into the intestinal microbial mass and excreted as such. The absorbed [l]{.smallcaps}‐lysine will be incorporated into body protein or excreted as urea/uric acid and as carbon dioxide.

The use of amino acids in water for drinking, in addition to complete diets with a well‐balanced amino acid profile may represent a risk for the target species due to nutritional imbalances and hygienic reasons (EFSA FEEDAP Panel, [2010](#efs25886-bib-0003){ref-type="ref"}). Moreover, it may result in an increased nitrogen excretion via urine. Therefore, the FEEDAP Panel has concerns on the safety of the use of lysine‐containing additives via water for drinking.

The FEEDAP Panel concludes that both forms of [l]{.smallcaps}‐lysine produced either by *C. glutamicum* NRRL B‐67439 or NRRL B‐67535 are safe for the target species, for the consumer and for the environment.

### 3.4.3. Safety for the user {#efs25886-sec-0042}

No studies were submitted using the products under assessment as test items to support the safety for the user.

#### 3.4.3.1. Effects on the respiratory system of [l]{.smallcaps}‐lysine HCl {#efs25886-sec-0043}

As regards [l]{.smallcaps}‐lysine HCl produced using strain NRRL B‐67439, the dusting potential may be up to 0.6 g/m^3^ and the fractions of particles \< 100, \< 50 and \< 10 μm diameter may be up to 3.7%, 2.8% and 1.4%, respectively (Section [3.2.2.2](#efs25886-sec-0015){ref-type="sec"}). The user may be exposed by inhalation. No study on acute inhalation toxicity was submitted.

Considering [l]{.smallcaps}‐lysine HCl produced using strain NRRL B‐67535, the dusting potential may be up to 4.6 g/m^3^ and the fractions of particles \< 100, \< 50 and \< 10 μm diameter may be up to 2.8%, 1.8% and \< 1%, respectively (Section [3.3.2.2](#efs25886-sec-0031){ref-type="sec"}). Although exposure via inhalation is possible, no study on acute inhalation toxicity was submitted.

In the absence of data is not possible to conclude on its potential to be toxic by inhalation.

#### 3.4.3.2. Effects on skin and eyes of [l]{.smallcaps}‐lysine HCl and concentrated liquid [l]{.smallcaps}‐lysine (base) {#efs25886-sec-0044}

The applicant provided acute dermal irritation/corrosion studies (in accordance with OECD Guideline 404), eye irritation/corrosion studies (in accordance with OECD 405) and kin sensitisation studies (in accordance with OECD Guideline 406) testing [l]{.smallcaps}‐lysin HCl and concentrated liquid [l]{.smallcaps}‐lysine base (3 studies per each form of the additive), where the test item was produced by a different production strain (*C. glutamicum* KCTC 12307BP).[74](#efs25886-note-1080){ref-type="fn"} ^,^ [75](#efs25886-note-1081){ref-type="fn"} Those studies had been previously assessed (EFSA FEEDAP Panel, [2019a](#efs25886-bib-0017){ref-type="ref"}).

As both production strains qualify for the QPS approach and there are no safety concerns related to their genetic modifications; the characteristics of the products and the manufacturing process are very similar, the FEEDAP Panel considers that the results of those studies are applicable to the products [l]{.smallcaps}‐lysine HCl under assessment. [l]{.smallcaps}‐Lysine HCl produced using *C. glutamicum* strain NRRL B‐67439 or strain NRRL B‐67535 is considered not irritant to skin and eyes and not a skin sensitiser.

Regarding the products concentrated liquid [l]{.smallcaps}‐lysine (base) under assessment, however, the Panel considers that the results of the acute dermal irritation/corrosion study, the eye irritation/corrosion study and the skin sensitisation study mentioned above cannot be extended to the concentrated liquid [l]{.smallcaps}‐lysine (base) produced using *C. glutamicum* strains NRRL B‐67439 or NRRL B‐67535, because the pH of these products is one point higher (10.7 and 10.9, respectively). The FEEDAP Panel considers that the products concentrated liquid [l]{.smallcaps}‐lysine (base) under assessment are corrosive to skin and eyes and pose a risk by inhalation.

#### 3.4.3.3. Conclusions on the safety for the user {#efs25886-sec-0045}

[l]{.smallcaps}‐Lysine HCl produced using *C. glutamicum* strain NRRL B‐67439 or strain NRRL B‐67535 is considered not irritant to skin and eyes and not a skin sensitiser. Due to the absence of data is not possible to conclude on its potential to be toxic by inhalation.

Concentrated liquid [l]{.smallcaps}‐lysine (base) produced using *C. glutamicum* strain NRRL B‐67439 or strain NRRL B‐67535, due to its high pH (10.7 and 10.9, respectively), is anticipated to be corrosive to skin and eyes and poses a risk by inhalation.

3.5. Efficacy of [l]{.smallcaps}‐lysine HCl and concentrated liquid [l]{.smallcaps}‐lysine (base) {#efs25886-sec-0046}
-------------------------------------------------------------------------------------------------

Efficacy studies are not required for amino acids naturally occurring in proteins of plants and animals. The nutritional role of the amino acid [l]{.smallcaps}‐lysine is well established in the scientific literature. The efficacy of [l]{.smallcaps}‐lysine for both non‐ruminant and ruminant species was described in two previous opinions (EFSA FEEDAP Panel, [2013](#efs25886-bib-0005){ref-type="ref"}, [2014](#efs25886-bib-0006){ref-type="ref"}). In general, the products concentrated liquid [l]{.smallcaps}‐lysine (base) and [l]{.smallcaps}‐lysine HCl are considered as efficacious sources of the essential amino acid [l]{.smallcaps}‐lysine for non‐ruminant animal species. For the supplemental [l]{.smallcaps}‐lysine to be as efficacious in ruminants as in non‐ruminant species, it would require protection against degradation in the rumen.

3.6. Post‐marketing monitoring {#efs25886-sec-0047}
------------------------------

The FEEDAP Panel considers that there is no need for specific requirements for a post‐market monitoring plan other than those established in the Feed Hygiene Regulation[76](#efs25886-note-1082){ref-type="fn"} and Good Manufacturing Practice.

4. Conclusions {#efs25886-sec-0048}
==============

The production strains (*C. glutamicum* strain NRRL B‐67439 and strain NRRL B‐67535) or their recombinant DNA were not detected in the respective final products. Therefore, the final products do not pose any safety concern associated with the genetic modification of these production strains.

[l]{.smallcaps}‐Lysine HCl and concentrated liquid [l]{.smallcaps}‐lysine (base) produced using *C. glutamicum* strain NRRL B‐67439 or strain NRRL B‐67535 do not represent a risk for the target species, for the consumer and for the environment. The Panel has concerns for the target species of the use of the additive in water for drinking.

[l]{.smallcaps}‐Lysine HCl produced using *C. glutamicum* strain NRRL B‐67439 or strain NRRL B‐67535 are considered not irritant to skin and eyes and not skin sensitisers. In the absence of data, the FEEDAP Panel cannot conclude on the potential toxicity by inhalation of [l]{.smallcaps}‐lysine HCl produced using these strains. Concentrated liquid [l]{.smallcaps}‐lysine (base) produced using *C. glutamicum* strain NRRL B‐67439 or strain NRRL B‐67535, due to their high pH (10.7 and 10.9, respectively), is anticipated to be corrosive to skin and eyes and poses a risk by inhalation.

[l]{.smallcaps}‐Lysine HCl and concentrated liquid [l]{.smallcaps}‐lysine (base) produced using *C. glutamicum* strain NRRL B‐67439 or strain NRRL B‐67535 are considered as efficacious sources of the essential amino acid [l]{.smallcaps}‐lysine for non‐ruminant animal species. For the supplemental [l]{.smallcaps}‐lysine to be as efficacious in ruminants as in non‐ruminant species, it would require protection against degradation in the rumen.

Chronology of the application for [l]{.smallcaps}‐lysine HCl and concentrated liquid [l]{.smallcaps}‐lysine (base) produced using *C. glutamicum* NRRL B‐67439 {#efs25886-sec-0049}
==============================================================================================================================================================

DateEvent21/03/2018Dossier received by EFSA: L‐Lysine HCl and concentrated liquid L‐lysine (base) produced using *Corynebacterium glutamicum* for all animal species. Submitted by ADM Speciality Ingredients (Europe) B.V.21/03/2018Reception mandate from the European Commission08/05/2018Application validated by EFSA -- Start of the scientific assessment20/06/2018Request of supplementary information to the applicant in line with Article 8(1)(2) of Regulation (EC) No 1831/2003 -- Scientific assessment suspended. *Issues: characterisation of the additive and safety for the user*.08/08/2018Comments received from Member States07/08/2018Reception of the Evaluation report of the European Union Reference Laboratory for Feed Additives20/06/2018Request of supplementary information to the applicant in line with Article 8(1)(2) of Regulation (EC) No 1831/2003 -- *Issues: Characterisation of the production strain*14/05/2019Reception of supplementary information from the applicant ‐ Scientific assessment re‐started07/10/2019Spontaneous submission of supplementary information07/10/2019Opinion adopted by the FEEDAP Panel. End of the Scientific assessment

Chronology of the application for [l]{.smallcaps}‐lysine HCl and concentrated liquid [l]{.smallcaps}‐lysine (base) produced using *C. glutamicum* NRRL B‐67535 {#efs25886-sec-0050}
==============================================================================================================================================================

DateEvent08/06/2018Dossier received by EFSA: L‐Lysine HCl and concentrated liquid L‐lysine (base) produced using *Corynebacterium glutamicum* for all animal species. Submitted by ADM Speciality Ingredients (Europe) B.V.19/06/2018Reception mandate from the European Commission01/10/2018Application validated by EFSA -- Start of the scientific assessment26/10/2018Request of supplementary information to the applicant in line with Article 8(1)(2) of Regulation (EC) No 1831/2003 -- Scientific assessment suspended. *Issues: characterisation the formulated additives, safety for the user*.13/12/2018Reception of the Evaluation report of the European Union Reference Laboratory for Feed Additives01/01/2019Comments received from Member States14/05/2019Reception of supplementary information from the applicant ‐ Scientific assessment re‐started07/10/2019Opinion adopted by the FEEDAP Panel. End of the Scientific assessment

Abbreviations {#efs25886-sec-0051}
=============

AFCEFSA Panel on Flavourings, Processing Aids and Materials in Contact with FoodAMRantimicrobial resistanceCASChemical Abstracts ServiceCEFEFSA Panel on Contact materials, Enzymes, Flavourings and Processing AidsCFUcolony forming unitCVcoefficient of variationDMdry matterDONdeoxynivalenolEINECSEuropean Inventory of Existing Commercial Chemical SubstancesEURLEuropean Union Reference LaboratoryFCCFood Chemical CodexFEEDAPEFSA Panel on Additives and Products or Substances used in Animal FeedFLAVISThe EU Flavour Information SystemIEC‐VIS/FLDion exchange chromatography coupled to visible or fluorescence detectionIUPACInternational Union of Pure and Applied ChemistryLC/MSliquid chromatography/mass spectrometryLODlimit of detectionLOQlimit of quantificationMICminimum inhibitory concentrationNDAEFSA Panel on Food additives and Nutrient Sources added to FoodOECDOrganisation for Economic Co‐operation and DevelopmentPCBpolychlorinated biphenylsPCDDspolychlorinated dibenzodioxinsQPSQualified Presumption of SafetyRSDrrelative standard deviation for repeatabilityRSDRrelative standard deviation for reproducibilityTEQtoxic equivalentWGSwhole genome sequenceWHOWorld Health Organization

Annex A -- Executive summary of the Evaluation Report of the European Union Reference Laboratory for Feed Additives on the Methods of Analysis for [l]{.smallcaps}‐lysine monohydrochloride and concentrated liquid [l]{.smallcaps}‐lysine produced by *Corynebacterium glutamicum* NRRL B‐67439 {#efs25886-sec-1001}
================================================================================================================================================================================================================================================================================================

 {#efs25886-sec-0052}

In the current application, authorisation is sought under Article 4(1) for [l]{.smallcaps}‐lysine monohydrochloride and concentrated liquid [l]{.smallcaps}‐lysine produced by *Corynebacterium glutamicum* NRRL B‐67439, under the category/functional group 3(c) 'nutritional additives'/'amino acids, their salts and analogues', according to Annex I of Regulation (EC) No 1831/2003. Authorisation is sought for all animal species.

For the quantification of lysine in the feed additive the Applicant submitted the ring‐trial validated method EN ISO 17180:2013 based on ion exchange chromatography coupled to visible or fluorescence detection (IEC‐VIS/FLD). This standard method does not distinguish between the salts of amino acids and it cannot differentiate between enantiomers. It applies for products containing more than 10% of amino acid. The following performance characteristics are reported: a relative standard deviation for repeatability (RSDr) ranging from 0.7% to 1.7% and a relative standard deviation for reproducibility (RSDR) ranging from 1.5% to 2.5%. In addition, the EURL identified the '[l]{.smallcaps}‐lysine monohydrochloride monograph' of the Food Chemical Codex (FCC) for the identification of [l]{.smallcaps}‐lysine monohydrochloride in the feed additive.

For the quantification of [l]{.smallcaps}‐lysine in premixtures, feedingstuffs and water the Applicant submitted the ring‐trial validated Community method (Commission Regulation (EC) No 152/2009) based on Ion Exchange Chromatography coupled with photometric detection (IECVIS). This method, designed only for the analysis of amino acids in premixtures and feedingstuffs, does not distinguish between the salts and the amino acid enantiomers. The following performance characteristics were reported for the quantification of total lysine: RSDr ranging from 2.1% to 2.8% and RSDR ranging from 3% to 6.7%.

In the frame of the stability studies, the Applicant presented experimental data obtained analysing lysine in water with the slightly modified AOAC official method 999.13 based on IEC‐VIS/FLD. The results presented are considered sufficient to demonstrate the suitability of the procedure for the analysis of the amino acid in water. Hence, the EURL recommends for official control this method to quantify lysine in water.

In the frame of this authorisation, the EURL recommends for official control (i) the '[l]{.smallcaps}‐lysine monohydrochloride monograph' of the Food Chemical Codex (FCC) based on infrared absorption for the identification of [l]{.smallcaps}‐lysine monohydrochloride in the feed additive; (ii) the ring‐trial validated method EN ISO 17180:2013 based on IEC‐VIS/FLD to quantify free lysine in the feed additive and premixtures (containing more than 10% lysine); (iii) the Community method based on IEC‐VIS for the quantification of lysine in premixtures and feedingstuffs; and (iv) the modified AOAC method based on IEC‐VIS/FLD to quantify lysine in water.

Further testing or validation of the methods to be performed through the consortium of National Reference Laboratories as specified by Article 10 (Commission Regulation (EC) No 378/2005) is not considered necessary.

Annex B -- Executive Summary of the Evaluation Report of the European Union Reference Laboratory for Feed Additives on the Methods of Analysis for [l]{.smallcaps}‐lysine monohydrochloride and concentrated liquid [l]{.smallcaps}‐lysine produced by *Corynebacterium glutamicum* NRRL B‐67535 {#efs25886-sec-1002}
================================================================================================================================================================================================================================================================================================

 {#efs25886-sec-0053}

In the current application authorisation is sought under Article 4(1) for [l]{.smallcaps}‐lysine monohydrochloride and concentrated liquid [l]{.smallcaps}‐lysine produced by *Corynebacterium glutamicum* NRRL‐B‐67535, under the category/functional group 3(c) 'nutritional additives'/'amino acids, their salts and analogues', according to Annex I of Regulation (EC) No 1831/2003. Authorisation is sought for all animal species.

According to the Applicant, the dry crystalline powdered [l]{.smallcaps}‐lysine monohydrochloride has a minimum purity (mass fraction) of 98.5% (minimum of 78.5% of [l]{.smallcaps}‐lysine) and concentrated liquid [l]{.smallcaps}‐lysine contains a minimum of 50% of [l]{.smallcaps}‐lysine.

The two forms of the feed additive are intended to be added directly into feedingstuffs (or through premixtures) and water for drinking. However the Applicant did not propose any minimum or maximum content of [l]{.smallcaps}‐lysine in feedingstuffs or water.

For the quantification of lysine in the feed additive, the Applicant submitted the ring‐trial validated method EN ISO 17180:2013 based on ion exchange chromatography coupled to visible or fluorescence detection (IEC‐VIS/FLD). This standard method does not distinguish between the salts of amino acids and it cannot differentiate between enantiomers. It applies for products containing more than 10% of amino acid. The following performance characteristics are reported: a relative standard deviation for repeatability (RSDr) ranging from 0.7% to 1.7% and a relative standard deviation for reproducibility (RSDR) ranging from 1.5% to 2.5%. In addition, the EURL identified the '[l]{.smallcaps}‐lysine monohydrochloride monograph' of the Food Chemical Codex (FCC) for the identification of [l]{.smallcaps}‐lysine monohydrochloride in the feed additive.

For the quantification of [l]{.smallcaps}‐lysine in premixtures, feedingstuffs and water the Applicant submitted the ring‐trial validated Community method (Commission Regulation (EC) No 152/2009) based on IEC coupled with photometric detection (IEC‐VIS). This method, designed only for the analysis of amino acids in premixtures and feedingstuffs, does not distinguish between the salts and the amino acid enantiomers. The following performance characteristics were reported for the quantification of total lysine: RSDr ranging from 2.1% to 2.8% and RSDR ranging from 3% to 6.7%.

In the frame of the stability studies, the Applicant presented experimental data obtained by analysing lysine in water with the slightly modified AOAC official method 999.13 based on IEC‐VIS/FLD. The results presented are considered sufficient to demonstrate the suitability of the procedure for the analysis of the amino acid in water.

In the frame of this authorisation, the EURL recommends for official control (i) the '[l]{.smallcaps}‐lysine monohydrochloride monograph' of the Food Chemical Codex (FCC) based on infrared absorption for the identification of [l]{.smallcaps}‐lysine monohydrochloride in the feed additive; (ii) the ring‐trial validated method EN ISO 17180:2013 based on IEC‐VIS/FLD to quantify free lysine in the feed additive and premixtures (containing more than 10% lysine); (iii) the Community method based on IEC‐VIS for the quantification of lysine in premixtures and feedingstuffs; and (iv) the modified AOAC method based on IEC‐VIS/FLD to quantify lysine in water.

Further testing or validation of the methods to be performed through the consortium of National Reference Laboratories as specified by Article 10 (Commission Regulation (EC) No 378/2005), as last amended by Regulation (EU) 2015/1761) is not considered necessary.
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Commission Regulation (EC) No 429/2008 of 25 April 2008 on detailed rules for the implementation of Regulation (EC) No 1831/2003 of the European Parliament and of the Council as regards the preparation and the presentation of applications and the assessment and the authorisation of feed additives. OJ L 133, 22.5.2008, p. 1.

■■■■■

■■■■■

■■■■■

■■■■■

■■■■■

■■■■■

■■■■■

■■■■■

■■■■■

■■■■■

FAD‐2018‐0012/Technical dossier/Section 2.1.3 and annex 2.1.3.

FAD‐2018‐0012/Technical dossier/Section II/Annex 2.1.3b. Lysine analysed using AOAC official method 999.13.

FAD‐2018‐0012/Technical dossier/Section II/Annex 2.1.3a. LC/MS identified material including adenine, guanine, cytosine, thymine, uracil, valerolactam, 2.3‐butanediol, *N*(alpha)‐acetyl‐lysine, *N*(epsilion)‐acetyl‐lysine, *N*‐acetyl‐cadaverine, *N*,*N*‐diacetyl‐cadaverine, phenyllactic acid, polypropylene glycol, 2‐isopropylmalic acid, 2‐isopropylmaleic acid, lysine dimer, hypoxanthine and aminocaprolactam.

FAD‐2018‐0012/Technical dossier/Section II/Annex 2.1.3b.

FAD‐2018‐0012/Technical dossier/Supplementary information May 2019/Annexes 4a to 4e.

FAD‐2018‐0012/Technical dossier/Section II/Annex 2.1.4c. LOD (in µg/kg) was 10 for arsenic, cadmium and lead and 0.17 for mercury.

FAD‐2018‐0012/Technical dossier/Supplementary information October 2019.
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FAD‐2018‐0012/Technical dossier/Section II/Annex 2.5.2a.

FAD‐2018‐0012/Technical dossier/Supplementary information May 2019/Annexes 3a1 to 3c1.

FAD‐2018‐0012/Technical dossier/Supplementary information May 2019/Annexes 2a to 2c.

FAD‐2018‐0012/Technical dossier/Supplementary information May 2019/Annexes 3a2 to 3c2.

FAD‐2018‐0012/technical dossier/Annex 2.1.3.a. Lysine analysed using AOAC 999.13 method.

FAD‐2018‐0012/Technical dossier/Annex 2.1.3.a. LC/MS identified material includes adenine, guanine, cytosine, thymine, uracil, valerolactam, 2.3‐butanediol, *N*(alpha)‐acetyl‐lysine, *N*(epsilon)‐acetyl‐lysine, *N*‐acetyl‐cadaverine, *N*,*N*‐diacetyl‐cadaverine, phenyllactic acid, polypropylene glycol, 2‐isopropylmalic acid, 2‐isopropylmaleic acid, lysine dimer, hypoxanthine and aminocaprolactam.

FAD‐2018‐0012/Technical dossier/Section II/Annex 2.1.4c. LOD (in µg/L) was 10 for arsenic, cadmium and lead and 0.17 for mercury.

FAD‐2018‐0012/Technical dossier/Supplementary information May 2019/Annexes 6a to 6e.

FAD‐2018‐0012/Technical dossier/Section II/Annex 2.5.2b.

FAD‐2018‐0012/Technical dossier/Section II/Annex 2.1.4m.

FAD‐2018‐0012/Technical dossier/Supplementary information May 2019/Annexes 7a to 7c.

FAD‐2018‐0012/Technical dossier/Supplementary information May 2019/Annexes 7d to 7e.

FAD‐2018‐0012/Technical dossier/Section 2.5.1.
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Technical dossier/Section 2.1.3 and Annex 2.1.3.

Technical dossier/Supplementary information May 2019/FAD‐2018‐0037 Sin 261018 and Add 180119 Answers 190506.

Technical dossier/Section II/Annex 2.1.3b. AOAC official method 999.13.

Technical dossier/Section II/Annex 2.1.3a. LC/MS identified material including adenine, guanine, cytosine, thymine, uracil, valerolactam, 2.3‐butanediol, *N*(alpha)‐acetyl‐lysine, *N*(epsilion)‐acetyl‐lysine, *N*‐acetyl‐cadaverine, *N*,*N*‐diacetyl‐cadaverine, phenyllactic acid, polypropylene glycol, 2‐isopropylmalic acid, 2‐isopropylmaleic acid, lysine dimer, hypoxanthine and aminocaprolactam.

Technical dossier/Section II/Annex 2.1.3b.

Technical dossier/Supplementary information May 2019/Annexes 2a to 2e. The range specified in the food chemicals code of the United States Pharmacopoeia (2010) is from +20.3 to +21.5°.

Technical dossier/Section II/Annex 2.1.4b. LOD (in µg/kg) was 10 for arsenic, cadmium lead and antimony; and 0.17 for mercury.

Technical dossier/Supplementary information May 2019/Annexes 2a to 2e.

Technical dossier/Section II/Annex 2.1.4a. LOD in µg/kg were 0.5 for aflatoxin B1, 0.3 for aflatoxin B2, 0.07 for aflatoxin G1, 0.09 for aflatoxin G2, 0.8 for ochratoxin A, 0.7 for zearalenone, 4 for fumonisin B1, 10 for fumonisin B2, 8 for fumonisin B3, 10 for DON and 9 for T‐2 toxin.

Technical dossier/Section II/Annex 2.1.4a.
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Technical dossier/Section II/Annex 2.5.2a.

Technical dossier/Supplementary information May 2019/Annexes 3a1 to 3c1.

Technical dossier/Supplementary information May 2019/Annexes 4a to c.

Technical dossier/Supplementary information May 2019/Annexes 3a1 to 3c2.

Technical dossier/Section II/Annex 2.4.1h.

Technical dossier/Section 2.1.3.

Technical dossier/Section II/Annex 2.1.3a. L‐lysine analysed by AOAC method 999.13.

Technical dossier/Section II/Annex 2.1.3a. 1.7% of liquid chromatography--mass spectrometry (LC--MS) identified material including adenine, guanine, cytosine, thymine, uracil, valerolactam, 2.3‐butanediol, *N*(alpha)‐acetyl‐lysine, *N*(epsilion)‐acetyl‐lysine, *N*‐acetyl‐cadaverine, *N*,*N*‐diacetyl‐cadaverine, phenyllactic acid, polypropylene glycol, 2‐isopropylmalic acid, 2‐isopropylmaleic acid, lysine dimer, hypoxanthine and aminocaprolactam.

Technical dossier/Section II/Annex 2.1.4b. LOD (in µg/L) was 10 for arsenic, cadmium, lead and antimony; and 0.17 for mercury.

Technical dossier/Supplementary information May 2019/Annexes 6a to e.

Technical dossier/Section II/Annex 2.1.4a. LOD (in µg/L) was 0.07 for aflatoxin G1, 0.09 for aflatoxin G2, 0.3 for aflatoxin B2, 0.5 for aflatoxin B1, 0.8 for ochratoxin A, 4 for fumonisin B1, 7 for zearalenone, 8 for fumonisin B3, 9 for T‐2 toxin and 10 for fumonisin B2 and for deoxynivalenol.

Technical dossier/Section II/Annex 2.5.2b.

Technical dossier/Section II/Annex II.1.4k.

Technical dossier/Supplementary information May 2019/Annexes 7a to f.

FAD‐2018‐0012/Technical dossier/Section III/Annex 3.3.1.2.a, annex 3.3.1.2.b and annex 3.3.1.2.c.

FAD‐2018‐0037/Technical dossier/Section III/Annex 3.3.1.2.a, annex 3.3.1.2.b and annex 3.3.1.2.c; and Supplementary information May 2019/Annexes 5b to 5c.

Regulation (EC) No 183/2005 of the European Parliament and of the Council of 12 January 2005 laying down requirements for feed hygiene. OJ L 35, 8.2.2005, p. 1.
